Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases.
The last earnings update was 155 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Immune Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Immune Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immune Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Immune Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Immune Pharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Immune Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Immune Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Immune Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Immune Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Immune Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Immune Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Immune Pharmaceuticals's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Immune Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are 0x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Gary H. Rabin is Chief Executive Officer, President and Director of Immune Pharmaceuticals, Inc. since March 2019. He was Interim Chief Executive Officer of Immune Pharmaceuticals, Inc. in 2019. He has a 32-year career in finance, investing, biotechnology management, and financial restructuring. He has been the Managing Member of Vine Holdings Group since 2015. He has also been the portfolio manager of three hedge funds in the tech/media/telecom sector. From 1987 until 2002, he was a media and telecom investment banker for some of the world's largest investment banking firms including CIBC, ING Barings, UBS and First Boston. Mr. Rabin served as Growth Strategist Officer of Flitways Technology, Inc. since April 2017. Mr. Rabin leads of FlitWays global growth initiatives and work with the FlitWays team to become the preeminent global ground transportation solution provider for businesses and corporations. He serves as Managing Partner of Vine Holdings. He served as the Chief Executive Officer of Ocata Therapeutics, Inc. (alternate name, Advanced Cell Technology Inc.) from December 14, 2010 to January 21, 2014. Mr. Rabin served as Principal Financial Officer of Ocata Therapeutics, Inc. since May 2013 and also served as its Principal Accounting Officer and Interim Chief Executive Officer. Mr. Rabin served as a Portfolio Manager of MAC Investment Management, LLC (MAC) until July 2007, which he joined in November 2005. Mr. Rabin Founded ING Barings Furman Selz LLC and served as Managing Director and Head of the Global Telecom Investment Banking Group from May 1997 to April 1999. He served at Ardent Communications Inc. He served as founding member of the telecom group at UBS Securities LLC. Previously, he served as a Managing Director and Portfolio Manager at Marketus Associates, a long/short hedge fund where he focused on communications, healthcare services, energy and special situations. Prior to that, he served as Managing Director and Co-Head of the Media and Telecom Investment Banking Group at CIBC World Markets (CIBC), where he was responsible for all corporate finance and M&A, financial restructurings and principal investing activities (both debt and equity) within the sector. Before joining CIBC, Mr. Rabin served as Chief Strategy Officer of CAIS Internet, Inc. (CAIS). From July 1989 through April 1994 he was a Principal of Beale Lynch Partners LLC. He began his career in finance in 1987 and concentrated on energy, utilities and metals until 1993. Throughout his career, Mr. Rabin has been responsible for building and developing businesses. He served at The First Boston Corporation, the Sumitomo Bank Limited and Manufacturers Hanover Trust Company. Mr. Rabin has twenty year career in finance that primarily encompasses investment management and capital raising targeting small-cap and emerging growth companies. Mr. Rabin served as the Chairman of Ocata Therapeutics, Inc. from September 2013 to January 21, 2014 and served as its Interim Chairman since December 14, 2010. Mr. Rabin served as an Independent Director of Ocata Therapeutics, Inc. from December 2007 to January 21, 2014. Mr. Rabin earned an AB in Economics from the University of Michigan.
Insufficient data for Gary to compare compensation growth.
Insufficient data for Gary to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Immune Pharmaceuticals management team is less than 2 years, this suggests a new team.
Controller & Principal Accounting Officer
Interim CEO & Director
Director of Investor Relations
Director of Corporate Affairs
President of Immune Oncology Pharmaceuticals Inc
Executive Director of R&D & Scientific Partnerships
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Immune Pharmaceuticals board of directors is about average.
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company’s lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company’s pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On February 17, 2019, Immune Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.